CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Nintedanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02568449
NCT02568449Phase 2Completed
CompareCT.gov

A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma

Barbara Ann Karmanos Cancer Institute·interventional·Posted Oct 5, 2015·Updated Dec 9, 2021

In Brief

A Phase 2 clinical trial evaluating Nintedanib for Recurrent Pleural Malignant Mesothelioma and Stage IV Pleural Mesothelioma. Completed, enrolled 20 participants across 3 sites.

Detailed Summary

This phase II trial studies how well nintedanib works in treating patients with malignant pleural mesothelioma that has come back. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Pleural Malignant Mesothelioma, Stage IV Pleural Mesothelioma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 5, 2015
Enrollment StartMar 15, 2016
Primary CompletionJan 1, 2017
Study CompletionJun 26, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.7 years ago

Interventions

Nintedanibdrug

Given PO